Loading...

Home
ETF
RNAZ

RNAZ

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

RNAZ News

TransCode Enters Exclusive License Agreement with Unleash Immuno Oncolytics

Mar 03 2026PRnewswire

TransCode Publishes Novel Tumor Immunotherapy Research

Feb 23 2026PRnewswire

TransCode Publishes TTX-MC138 Research for Glioblastoma Treatment

Jan 06 2026PRnewswire

TransCode's TTX-MC138 Significantly Extends Survival in Glioblastoma Mouse Models

Jan 06 2026Newsfilter

TransCode Appoints Jack E. Stover to Board of Directors, Enhancing Leadership Experience

Dec 22 2025PRnewswire

TransCode Appoints Jack E. Stover to Board, Enhancing Oncology Expertise

Dec 22 2025Newsfilter

TransCode's TTX-MC138 Set to Begin Phase 2a Trial Within Quantum Leap PRE-I-SPY Initiative

Dec 12 2025NASDAQ.COM

TransCode Partners with Quantum Leap for TTX-MC138 Phase 2a Clinical Trial

Dec 11 2025Newsfilter

TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

Nov 17 2025PRnewswire

TransCode Purchases Polynoma from CK Life Sciences

Oct 08 2025NASDAQ.COM

TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company

Oct 08 2025PRnewswire

FedEx Shares Rise 5%; Check Out 20 Stocks Making Moves in Premarket Trading

Sep 19 2025Benzinga

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

May 28 2025PRnewswire

Upcoming Stock Splits This Week (May 12 to May 16) – Stay Invested

May 11 2025TipRanks

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

May 08 2025Newsfilter

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

May 05 2025Newsfilter